Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
AN INVESTIGATION OF OVULATION INHIBITION WITH A LOW-DOSE COMBINED ORAL-CONTRACEPTIVE CONTAINING 75 MU-G GESTODENE AND 20 MU-G ETHINYLESTRADIOL
Autore:
ARCHER DF; GAST MJ;
Indirizzi:
JONES INST WOMENS HLTH NORFOLK VA 23507
Titolo Testata:
Gynecological endocrinology
, volume: 12, anno: 1998, supplemento:, 4
pagine: 7 - 12
SICI:
0951-3590(1998)12:<7:AIOOIW>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
CYCLE CONTROL; DESOGESTREL; ESTROGEN; EFFICACY;
Keywords:
ORAL CONTRACEPTIVES; OVULATION INHIBITION; GESTODENE; HYPOTHALAMIC-PITUITARY-OVARIAN AXIS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
10
Recensione:
Indirizzi per estratti:
Citazione:
D.F. Archer e M.J. Gast, "AN INVESTIGATION OF OVULATION INHIBITION WITH A LOW-DOSE COMBINED ORAL-CONTRACEPTIVE CONTAINING 75 MU-G GESTODENE AND 20 MU-G ETHINYLESTRADIOL", Gynecological endocrinology, 12, 1998, pp. 7-12

Abstract

This open-label, single-center study investigated the efficacy of a 21-day monophasic oral contraceptive containing 75 mu g gestodene and 20 mu g ethinylestradiol with respect to its effects on the hypothalamic-pituitary-ovarian axis and ovulation inhibition. A total of 38 healthy women between the ages of 21 and 34 years entered the study, which consisted of two control cycles (cycles 1 and 5) and three treatment cycles (cycles 2, 3 and 4). During treatment, each subject received thecontraceptive preparation once a day for 21 days followed by 7 days of placebo. Ovulation was inhibited in all 79 treatment cycles, as defined by ultrasound measurements of follicle size greater than or equal to 16 mm diameter and by serum levels of progesterone > 5 ng/ml in a single cycle. Luteinizing hormone, follicle stimulating hormone and 17 beta-estradiol were also suppressed by the treatment. The greatest suppressive effect on ovarian follicular activity was observed in cycle 2, where treatment with gestodene/ethinylestradiol began on day 1 of the menstrual cycle. There were no serious adverse events. Results from this study demonstrate that this low-dose combined oral contraceptive is effective as an inhibitor of ovulation, by suppressing the activityof the hypothalamic-pituitary-ovarian axis.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/10/20 alle ore 08:09:34